RARE — Ultragenyx Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- $1.87bn
- $2.35bn
- $673.00m
Annual cashflow statement for Ultragenyx Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -454 | -707 | -607 | -569 | -575 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 165 | 249 | 121 | 106 | 97 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -63.2 | 61.9 | -13.5 | 13.9 | -23 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -339 | -380 | -475 | -414 | -466 |
| Capital Expenditures | -73.1 | -146 | -46.8 | -20 | -21 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -122 | -146 | 215 | 2.22 | 257 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -195 | -292 | 168 | -17.8 | 236 |
| Financing Cash Flow Items | -0.492 | 490 | -0.028 | 7 | 392 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 119 | 501 | 388 | 399 | 478 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -417 | -172 | 81.8 | -35.2 | 252 |